Y-chromosome Degeneration due to Speciation and Founder Effect.

The Y chromosome in the XY sex-determination system is often shorter than its X counterpart, a condition attributed to degeneration after Y recombination ceases. Contrary to the traditional view of continuous, gradual degeneration, our study reveals stabilization within large mating populations. In these populations, we demonstrate that both mutant and active alleles on the Y chromosome can reach equilibrium through a mutation-selection balance. However, the emergence of a new species, particularly through the founder effect, can disrupt this equilibrium. Specifically, if the male founders of a new species carry only a mutant allele for a particular Y-linked gene, this allele becomes fixed, leading to the loss of the corresponding active gene on the Y chromosome. Our findings suggest that the rate of Y-chromosome degeneration may be linked to the frequency of speciation events associated with single-male founder events.

Correlation between gyral size, brain size, and head impact risk across mammalian species.

A study on primates has established that gyral size is largely independent of overall brain size. Building on this-and other research suggesting that brain gyrification may mitigate the effects of head impacts-our study aims to explore potential correlations between gyral size and the risk of head impact across a diverse range of mammalian species. Our findings corroborate the idea that gyral sizes are largely independent of brain sizes, especially among species with larger brains, thus extending this observation beyond primates. Preliminary evidence also suggests a correlation between an animal's gyral size and its lifestyle, particularly in terms of head-impact risk. For instance, goats, known for their headbutting behaviors, exhibit smaller gyral sizes. In contrast, species such as manatees and dugongs, which typically face lower risks of head impact, have lissencephalic brains. Additionally, we explore mechanisms that may explain how narrower gyral sizes could offer protective advantages against head impact. Finally, we discuss a possible trade-off associated with gyrencephaly.

Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysis.

Allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has the potential for extensive clinical applications. This study aimed to evaluate its efficacy and safety in treating relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Four databases were searched for relevant studies. Among patients treated with donor-derived CAR T-cell therapy, ALL patients had a complete remission (CR) rate of 80 % and a 1-year overall survival rate of 51 %. The graft-versus-host disease (GvHD) rate was 4 %, cytokine release syndrome was 69 %, and immune effector cell-associated neurotoxicity syndrome was 8 %. For off-the-shelf CAR T-cell therapy, the CR rate for ALL was 70 %, and for NHL, it was 52 %. The objective response rate for NHL was 72 %. The pooled GvHD of off-the-shelf CAR T-cell therapy for ALL and NHL combined was 0 %. Allogeneic anti-CD19 CAR T-cell therapy are effective and safe for treating R/R ALL and NHL. AVAILABILITY OF DATA AND MATERIALS: All datasets generated in this study are included in the article/Supplementary Material.